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Abstract 
BACKGROUND: An increase in urinary indolyl-3-acryloylglycine (IAG) has been reported 
in children with ASD who suffer with bowel problems in comparison to ASD children 
without gastrointestinal (GI) problems. The case for dietary intervention for ASD children 
with GI symptoms might be strengthened were such a difference to be autism-specific.  
METHODS: Quantitative analysis of urinary IAG levels was performed for 53 children on 
the autism spectrum and 146 age-matched controls. The parents of each child were asked to 
provide information on bowel symptoms experienced by the child and their eating habits over 
a period of two weeks.  
RESULTS: We find no significant difference in urinary IAG levels between the ASD 
children with GI problems and ASD children without GI problems. Although we see some 
difference between ASD children with GI problems and controls in mainstream schools with 
GI problems, the difference between non-autistic children with other developmental disorders 
and controls in mainstream schools is more significant so that any difference is not autism-
specific. We find a strong correlation between bowel symptoms and diet problems in ASD 
children, especially idiosyncratic feeding behaviour and we show that ASD children suffering 
from multiple bowel symptoms tend to be those who also have dietary problems. 
CONCLUSION: We found no evidence to support the hypothesis that children with ASD 
who suffer with bowel problems have increased levels of urinary indolyl-3-acryloylglycine in 
comparison to children with ASD who do not have gastrointestinal problems. 
 
Introduction 
Autism is a complex disorder characterised by language and communication 
difficulties, qualitative social reciprocity and restricted, repetitive, and stereotyped patterns of 
behaviour, interests and activities (1). Despite extensive research based on theories ranging 
from changes in brain structure (2) to genetic differences and metabolic disturbances (3), the 
aetiology is still unclear as no consistent pathophysiology for all autism spectrum disorders 
(ASDs) can be established. Several studies have been based on the hypothesis that some 
symptoms of autism may be associated with an excess of opioid-like peptides derived from 
dietary sources (4). Such proposals offer the potential for biomedical intervention, but 
conflicting evidence has been produced related to this Òopioid excess theoryÓ with no 
evidence of the neuropeptides found in children with or without ASD in the targeted analysis 
of Dettmer and associates (5).  
Although Kuddo and Nelson concluded that the frequency of gastrointestinal problems 
are much less frequent in children with autism than pediatric gastroenterology clinics report 
(6), several authors have found a strong association between bowel problems and autism in 
community samples (7-9). Specific symptoms, such as diarrhoea, constipation, foul-smelling 
stools, flatulence, abdominal bloating and discomfort have been identified and compared 
between children with autism and their healthy siblings (10, 11). In addition to an increased 
incidence of constipation, more issues with feeding and food selectivity have been reported 
for children with autism, suggesting the higher incidence of GI symptoms may be 
neurobehavioural, although a primary organic gastrointestinal origin cannot be ruled out (12). 
In their comparison, Chaidez and coworkers found that parents of children with ASD or 
developmental delay reported more food dislikes (selectivity), as well as more GI symptoms 
not explained by other factors, than parents of typically developing children (9). Their results 
also show significantly higher incidence of behavioural problems (irritability, social 
withdrawal, stereotypy and hyperactivity) in ASD children with GI problems than those 
without symptoms. A meta-analysis involving15 studies also concluded that children with 
ASD experience significantly more GI symptoms than comparison groups with higher rates of 
diarrhoea, constipation and abdominal pain, but no evidence of a unique pathology in ASD 
(13). Regardless of cause or effect, the association between diet and autism has been used to 
suggest treatment in the form of dietary intervention. In particular, some authors hypothesise 
that gluten- and casein-derived peptides may trigger an immune response resulting in GI 
symptoms (14). It has been noted that, for the majority of children diagnosed with autism, 
symptoms were observed before 18 months of age, giving a limited time period over which 
specific foods, particularly gluten, would have been eaten although the milk protein, casein, 
would have been ingested since birth (15). Although no large scale randomised controlled 
trials have taken place, some authors suggest that gluten-free and/or casein-free (GFCF) diets 
can be effective in some children with autism (16, 17). However, the findings are not 
reproduced in other studies (18, 19) and a recent double-blind trial found no significant effect 
on behaviour or autism symptoms (20). Black and coworkers found no evidence that, before 
their diagnosis, children with autism were more likely to have had gastrointestinal disorders 
than children without autism (21). Although a decrease in urinary peptide secretion has been 
reported in response to diet as well as improvement in behaviour and a decrease in epileptic 
seizures (22), it has also been observed that the evidence is weak and that GFCF diets should 
only be recommended after intolerance or allergy to foods containing the allergens excluded 
in these diets has been diagnosed (23). Faddy or selective eating (also known as perseverant 
eating) is often associated with ASDs and many children with autism reject foods based on 
their texture, colour or other characteristics, potentially leading to nutritional deficiencies 
(24). A comprehensive meta-analysis, involving 17 studies with a comparison group, revealed 
that children with ASD experience significantly more feeding problems and have significantly 
lower intake of calcium and protein (25). This risk may increase if further dietary restrictions 
are imposed on children with ASD. Until specific evidence-based guidelines have been 
developed, Buie and coworkers recommend that general pediatric guidelines for diagnostic 
evaluation of abdominal pain, chronic constipation, and gastroesophageal reflux disease be 
adapted for children with ASDs (26). Sharp and colleagues encourage clinicians to assess 
feeding problems in children with ASD and to screen for nutritional deficiencies as well as 
educating caregivers in the potential consequences of following elimination diets (25). 
In the context of proposed bowel and metabolism problems in autism some have 
suggested that the metabolite, indolyl-3-acryloylglycine (IAG), has been found in the urine of 
children with ASD, and may be a putative marker for autism and tryptophan metabolism 
problems (27). However, this study had no comparison to a control group to establish its 
specificity to the disorder. In a comparative study, IAG was proposed as a putative diagnostic 
marker for ASD (28). However, Wright and associates found no statistically significant 
difference in the levels of urinary IAG between children with ASD and controls without ASD 
(29). More recently, a link between gastrointestinal (GI) dysfunction in autism and urinary 
IAG has been suggested, with IAG levels raised only in those ASD children exhibiting bowel 
symptoms (30). Furthermore, as no such difference was found between control children with 
and without bowel problems, these authors suggest that increased IAG levels could be autism-
specific. If true, such findings could support the hypothesis that problems with digestion lead 
to symptoms of autism arising from an excess of opioid-like peptides and that dietary 
intervention might help ASD children with GI symptoms. 
Here we investigate the hypothesis that children with ASD who suffer with bowel 
problems have increased levels of urinary indolyl-3-acryloylglycine in comparison to children 
with ASD who do not have gastrointestinal problems. We also consider the relationship 
between bowel symptoms, diet and dietary problems and faddy eating in ASD children. 
 
Results 
We compared IAG levels and the results of a bowel symptom questionnaire between a 
group of children with autism, a control group of normal healthy children and a third group, 
consisting of children with other developmental disorders attending special schools, but who 
had not been diagnosed with autism. For each child with a full bowel data set, a positive 
response to any of questions A2, A3, A5, A7 and A8 on the questionnaire (see Methods) was 
considered to suffer from gastrointestinal problems. These questions correspond to the 
question used in the study by (30) to determine whether a child had GI problems: ÔDoes your 
child have any chronic/on-going gastrointestinal issues i.e. bloating, diarrhoea, constipation, 
excessive flatulence, abdominal pain?Õ (The comparisons made between groups are 
summarised in Table 1).   
 
Do ASD children with GI symptoms have higher levels of urinary IAG than ASD 
children without GI symptoms? 
We found no significant difference in mean IAG level between the ASD children with 
GI problems and ASD children without GI problems (t-test p = 0.20). Similarly, we found no 
significant difference between the controls with GI problems and controls without GI 
problems (t-test p = 0.93), (the boxplots in figure 1 show the distribution of 
ln(IAG:creatinine) for the children with ASD and the controls, with and without GI problems 
in each case). Here the controls include both mainstream and special school groups, but we 
also found no significant difference between children with and without GI problems in either 
the mainstream school group (t-test p = 0.08) or the special school group (t-test p = 0.37) 
when considered separately.  
Stepwise regression with our data starting with the five covariates corresponding to 
the Wang study leads to a model that only includes constipation and abdominal pain as 
covariates related to age-adjusted IAG levels. Although the p-value of 0.05 might suggest that 
the regression is just about significant, the R
2
 value of 0.03 shows that the model is a very 
poor fit, accounting for little of the variance in the data. The low p-value is mainly due to a 
number of unusually high IAG levels having undue influence. We also analysed the additional 
bowel data on recurrent vomiting, blood in stools, parental concerns about bowel habit and 
whether children had ever been assessed or treated by a bowel specialist or diagnosed with a 
bowel disorder. Again we found no evidence of increased levels of IAG in children with ASD 
suffering from any particular symptom or subset of symptoms.  
 
Do ASD children with GI symptoms have higher levels of urinary IAG than control 
children with GI symptoms? 
Considering only children with GI problems, a studentÕs t-test shows the difference in 
means between the children with ASD and controls in mainstream schools to be statistically 
significant (p = 0.04) with higher levels in mainstream children (the box-plots in figure 2 
show the distributions of IAG levels for children with gastrointestinal problems). However, a 
Wilcoxon rank sum test does not give a significant result (p = 0.12). Furthermore, the mean 
for the control children in special schools is also significantly lower than that for controls in 
mainstream schools (t-test p = 0.004). In fact, a t-test shows no statistically significant 
difference between the children with ASD suffering from bowel problems and the control 
children in special schools suffering from bowel problems (p = 0.46) and when the two 
control groups are combined, there is no statistically significant difference between this group 
and the children with ASD (p = 0.60). 
 
Do ASD children with GI symptoms have more diet issues than ASD children without 
GI symptoms? 
For each child with a full bowel and diet history, a diet score was obtained from the 
level of agreement with statements 1 to 11 on the dietary questionnaire (figure 3 shows the 
distribution of diet scores for children with ASD with GI problems (n = 25) and children with 
ASD without GI problems (n = 18). A t-test shows the difference between the diet scores for 
ASD children with and without bowel problems to be statistically significant at the 95% 
confidence level (p = 0.01). We found no such difference in the control group, but with just 8 
of the 22 special school controls with full diet and bowel history having GI problems, the 
numbers are too small to draw any conclusions. 
 
Do ASD children with diet problems have more bowel problems than ASD children 
without diet problems? 
A child was considered to have dietary problems if the parent was concerned about the 
range of foods eaten or had seen a dietician for dietary advice for their child. A t-test shows a 
significant difference (p = 0.002) in bowel scores for children with ASD with and without 
dietary problems (the distribution of bowel scores, i.e. the number of reported bowel 
symptoms, is shown in figure 4 for ASD children with and without dietary problems). It can 
be seen that those children reported to be suffering from multiple bowel symptoms tend to be 
the children with more dietary issues. 
 
Do ASD children really have faddy eating habits? 
Parents were also asked to rate the effect of certain factors related to food types or 
products (D1 to D8 in the Appendix) on their childÕs food selectivity with a score between 0 
and 6 for each. A Òfood faddiness scoreÓ was calculated by summing these parental scores 
(figure 5 shows the faddiness scores plotted against diet scores for each group). There is a 
strong correlation between faddiness and diet score, particularly for ASD children with GI 
problems (r = 0.80). For ASD children without GI problems, the correlation is somewhat 
weaker (r = 0.60) as it is for children without autism in special schools with or without GI 
problems (r = 0.54 and r = 0.64 respectively). A χ2 test of the binary diet problem indicator 
(reflecting a positive response by the parent to either question C1 or C2 on the questionnaire) 
with the binary bowel score (indicating the presence or absence of bowel symptoms) shows a 
significant association between dietary problems and bowel problems in children with ASD (p 
= 0.0056).  
 
Discussion 
Significant differences in mean IAG:creatinine ratios were proposed in ASD children 
with on-going GI problems compared with ASD children without GI problems (30). 
Furthermore, as no significant difference was found between ASD children with GI problems 
and control children with on-going GI problems, Wang and colleagues concluded that raised 
IAG levels could be specific to autism. Such a difference could provide support for dietary 
intervention in those ASD children who also suffer from gastrointestinal problems. However, 
we found no evidence to support this.  There were no statistically significant differences in 
IAG:creatinine ratios whether only the five questions corresponding to the Wang study were 
used to determine the presence of GI problems or the additional questions from our more 
comprehensive bowel questionnaire were included.  
If the level of urinary indolyl-3-acryloylglycine was a useful biomarker for autism, 
even if only in children experiencing gastrointestinal problems, then a significant difference in 
urinary IAG between children with GI problems, with and without ASD would be required. 
That is, IAG levels for children with ASD and GI problems should be compared with children 
without ASD who have GI problems. Considering only children with GI problems, we find 
that both the children with ASD and the control children in special schools have lower IAG 
levels than the controls in mainstream schools, in direct contrast to the reported higher levels 
in ASD children (30). Moreover, we find no significant difference between IAG levels for 
ASD children and children with other learning disabilities, confirming the lack of evidence 
for an autism specific rise in IAG. This reflects the previous finding of Smith and colleagues 
that both groups show a similar increase in reported bowel symptoms in comparison to a 
control group in mainstream schools (8). Although bowel symptoms will occur with a wide 
range in severity, we use a binary indicator as our results rely on parentsÕ perceptions. 
However, Gorrindo and colleagues investigated parental reports of GI disorders relative to 
evaluations by pediatric gastroenterologists and found the parentsÕ views to be highly 
concordant with physiciansÕ diagnosis (31). The finding that children with learning 
disabilities and GI problems have lower IAG levels than those with GI problems in 
mainstream schools in mainstream schools is difficult to explain.  It is possible that this is to 
do with dietary intake (with many, but not all children with ASD, also in special schools) or to 
do with levels of activity leading to different metabolism or to some other common 
environmental factor.  It is noticeable that the participants in the special schools control group 
tend to be older than those in the other two groups: 46% of mainstream controls (and 38% of 
ASD children), are under 9 years of age in comparison to 29% of special school controls, 
whereas only 5% of mainstream controls (and 15% of ASD children) are over 12 years of age 
in comparison to 59% of special school controls. Although we obtained similar results after 
adjusting for age using the pooled population as the standard population, it could be that this 
has some effect.  
It is possible that the conflicting results could be due to sibling influence. It is 
interesting to note that, in the study of Wang and colleagues, 26% of sibling controls were 
reported to suffer from GI symptoms, in comparison to just 5% of their unrelated community 
controls, whereas 12% of our mainstream school controls and 38% of our special school 
controls report GI symptoms. In our study, 29/51 (57%) of children with ASD have GI 
problems compared with 26/57 (46%) in the Wang study. It is also possible that there are 
differences due to cohorts suffering from different symptoms, as for example, some children 
may suffer more from diarrhoea and others more from constipation. Molloy and Manning-
Courtney found diarrhoea to be the most common symptom in ASD children (32), whereas 
Ibrahim and colleagues report increased incidence of constipation (12). Analysis of our data 
shows rough equal numbers of children with ASD suffer from diarrhoea (14/51) and 
constipation (13/51) with 4 children reporting symptoms of both. We performed network 
analysis using an adjacency matrix obtained from the number of ASD children suffering from 
pairs of bowel symptoms (figure 6 shows the strength of the association between different 
bowel symptoms for children with ASD). It can be seen that excess flatulence is commonly 
associated with both diarrhoea and constipation, that the presence of blood in stools is most 
often associated with constipation and that abdominal pain is frequently associated with 
bloating. Instances of persistent diarrhoea (more than 3 weeks and more than 3 times a day) 
and recurrent vomiting were much less frequent. When any reported treatment for bowel 
symptoms was included in the network analysis, this was shown to be most associated with 
constipation, followed by abdominal pain and bloating, with diarrhoea related to treatment to 
a lesser extent. 
We find a strong association between dietary problems and gastrointestinal problems 
in children with ASD. The direction of this association is not possible to determine with 
accuracy but there is a considerable body of literature showing that extreme faddiness (33) 
and poor dietary intake (34, 35) in children has a significant impact on bowel habit. It is of 
course also possible that a primary bowel problem may influence dietary intake (17).  
However, in many children with ASD no formal bowel pathology has been consistently 
diagnosed (6). Indeed, Gorrindo and colleagues found bowel problems were not associated 
with seven-day food intake but were associated with social and language impairments (31).   
 
Conclusions 
We found no evidence to support the hypothesis that children with ASD who suffer 
with bowel problems have increased levels of urinary indolyl-3-acryloylglycine in 
comparison to children with ASD who do not have gastrointestinal problems. We also found 
no statistically significant difference in the IAG levels or IAG:creatinine ratios in controls 
with bowel problems compared to those without such symptoms, whether or not children in 
mainstream and special schools were considered separately. We find lower levels of urinary 
IAG in children with ASD suffering from GI problems than in control children in mainstream 
schools with GI problems, in direct contrast to the findings of Wang and colleagues (30), who 
report significantly higher levels of IAG in ASD children. Furthermore, we also found 
significantly lower levels of IAG in the control children in special schools with GI problems 
in comparison to the control children in mainstream schools with GI problems, so that any 
difference is not autism specific. 
Our research supports the view that GI abnormalities and unusual dietary preferences 
and behaviours may be associated in some children with autism but it is more likely that this 
is related to dietary intake, and faddiness and selectivity with secondary nu
than a primary bowel problem.  With this controversy in mind GI abnormalities should not be 
considered as a defining characteristic of autism (36). 
According to surveys, up to 40% of children with autism have been placed on 
special diets at some time (37). These can be dangerous in restricting healthy nutritional 
intake essential for brain and body development (38). Although some special diets, such as 
low-sugar diets, can be healthy, casein-free diets, for example, can be a concern due to 
decreased calcium intake. We urge caution until more definite research can be done into the 
relation between diet, bowel habit in ASD children and the role of nutritional intake. 
Although a number of potential biomarkers for autism have been suggested, there is currently 
insufficient evidence for urinary IAG to provide further insight into the aetiology or diagnosis 
of autism and that there is sufficient evidence for IAG to be used as a test to recommend 
dietary intervention whether this is in ASD children in general or in children with autism and 
GI problems. 
 
Methods 
Data collection 
A leaflet for parents and children was prepared to explain sample collection 
procedures using standardised equipment. Urine samples were blinded with code numbers and 
delivered from one of several points of collection to the Department of Chemical Pathology at 
York Hospital within 24 hours and stored at Ð20¡C. Each urine sample was divided into two 
parts. The first was used to perform quantitative analysis of IAG and the second for 
determination of the creatinine concentration using a standard method (39) on an Hitachi 917 
analyser (Boehringer, Mannheim, Germany). IAG:creatinine ratios were calculated to control 
for variations caused by body mass, urine concentration, and other metabolic factors. IAG 
was synthesised by a method adapted from (40), which involved esterification of indole-3-
acrylic acid with glycine methyl ester using dicyclohexylcarbodiimide and 
hydroxybenzotriazole in dichloromethane. In addition, a dideuterated analogue of IAG was 
synthesised by the same route according to a method by Tilley and associates (41). Analysis 
of urine samples for IAG was effected by using high performance liquid chromatography with 
tandem mass spectrometric detection. Dideuterated IAG was used as an internal standard. The 
method was validated according to internationally recognised standards (42) to ensure 
precision, accuracy, and specificity.  
As the distribution of IAG levels (measured in mmol) was skewed to the left, a 
constant of 0.001 was added before taking the natural logarithm to normalize the distribution. 
An IAG: creatinine ratio was calculated to allow for variations in urine concentration and the 
ratios also transformed by adding a constant of 0.001and taking the natural logarithm. After 
the transformation, Shapiro-Wilk tests showed that the data for each group were plausibly 
normal, making the use of StudentÕs t-tests valid. In addition we report results for the non-
parametric Wilcoxon rank sum test, which does not require the data to be normally 
distributed.   
The age distribution for the ASD group and for the mainstream school control group is 
very similar and neither group shows correlation between age and IAG levels (Table 1). 
Therefore, although Wang and colleagues report results for age-adjusted values (30), we have 
chosen not to perform this data manipulation. However, there are more older children and 
young adults in the special school control group with a slightly greater negative correlation 
with age. 
A questionnaire on bowel symptoms experienced by the child over a period of two 
weeks was given to parents at the time the childÕs urine sample was given. Standard 
definitions of symptoms were reviewed including WHO definitions of bowel problems such 
as diarrhoea. A meeting with a group of five consultant general pediatricians and two 
registrars further defined and agreed symptoms to be included. The following questions on 
bowel symptoms experienced by the child and noticed by the parent were included in the 
questionnaire: 
A1. Do you have any concerns about your child's bowels? 
A2. Does he/she have constipation? 
A3. Does he/she have diarrhoea? 
A4. Does he/she have persistent diarrhoea (more than 3 weeks and more than 3 
times a day)? 
A5. Does he/she complain of recurrent abdominal pain? 
A6. Does he/she have problems with recurrent vomiting? 
A7. Does he/she complain of abdominal distension or tummy bloating? 
A8. Does he/she have excessive flatulence? 
A9. Has there ever been any blood present in his her stools? 
A10. Have you ever seen a doctor specifically because of a concern that your child 
may have a bowel disorder? 
A11. Have you ever seen a doctor who specialises in bowel disorders? 
A12. Has your child been specifically diagnosed as having a bowel disorder? 
A13. Have you given your child a treatment because of a bowel problem? 
 
The Òbowel scoreÓ was calculated as the number of positive responses to these questions. 
Questions A2, A3, A5, A7 and A8 correspond to the questions used in the Wang study (30). 
 
Parents were also asked to fill in a questionnaire to provide information on their 
childÕs eating habits and preferences during the period over which the bowel data were 
collected. Parents were asked to assign a number between 0 (not at all) and 6 (definitely) to 
describe the truth of the following statements: 
B1. My child is very particular about what they eat. 
B2. My childÕs preferences lead to a very restricted diet. 
B3. My child intensely refuses foodstuffs that they prefer not to eat. 
B4. There are factors that affect my childÕs eating, making food preparation and 
feeding difficult. 
B5. My child shows an obsessive insistence to only eat foods that fit certain criteria. 
B6. Foodstuffs have to be strictly separated on the plate for my child to accept and 
consume them. 
B7.    My childÕs appetite varies greatly. 
B8. My child closely examines food served to them before accepting and consuming 
it.  
B9. My child eats foodstuffs in one place that they will not eat in another place, 
despite the food being similar. 
B10. My child is not happy eating at restaurants (not fast-food outlets). 
B11. My child shows an excessive desire to use condiments (e.g. Ketchup, salt, etc.) 
 
For each child with a full bowel and diet history, a Òdiet scoreÓ was obtained by summing the 
parental scores for these statements. 
 
In this study, a child is considered to have diet problems if the answer to either of the 
following questions from the questionnaire is positive: 
 
C1. Are you concerned about the range of foods that your child has in the diet? 
C2. Have you ever seen a dietician for dietary advice for your child? 
 
The Òdiet problem indicatorÓ is therefore zero, if the responses to questions C1 and C2 are 
both negative, and one otherwise.  
 
To determine the effect of various factors related to food types or products on a childÕs food 
selectivity, parents were asked to give a score between 0 and 6 to rate the effect of the 
following factors: 
D1. Appearance. 
D2. Colour. 
D3. Gimmicks. 
D4. Logos. 
D5. Packaging. 
D6. Smell. 
D7.    Taste. 
D8. Texture.  
The Òfaddiness scoreÓ was calculated by summing the parental scores for these statements. 
 
Participants  
Children and young people were recruited for a study into urine metabolites (29) by 
sending letters of invitation to all cases on the Autism Spectrum Disorders Forum register at 
York with a diagnosis of childhood autism, atypical autism or Asperger syndrome made using 
criteria from the World Health Organization International Classification of Diseases system 
version 10 (43). The diagnosis made through the multidisciplinary multi-agency ASD Forum 
involved consultant paediatricians, consultant child psychiatrists, consultant child 
psychologists, educational psychologists and speech and language therapists (44). In cases 
where the ICD-10 diagnosis could not be independently validated by at least two members of 
the Forum (72% of cases), the diagnosis was supported using the Autism Diagnostic 
InventoryÐRevised (ADI-R) and the Autism Diagnostic Observation ScheduleÐGeneric 
(ADOS) (45). This is the routine assessment and diagnosis protocol for the local 
multidisciplinary ASDs Forum.  
As controls, for each child or young person with ASD, at least one age and sex 
matched child or young person without autism was recruited from both a special school and a 
mainstream school. The children in the special schools group suffered from learning 
disabilities, but none were diagnosed with or were suspected by parents or teachers as having 
an autism spectrum disorder. Following consent from head-teachers and governors, the 
parents were circulated with a standard information leaflet inviting them to participate in the 
study. Informed consent was obtained from parents. Exclusion criteria included any known 
metabolic disorder and, for the non-autistic group, any previous assessment for an autism 
spectrum disorder.  
A total of 54 children on the autism spectrum participated, of which 51 had a complete 
bowel data set (94%) with 29 suffering from GI problems and 22 without GI problems. Using 
the estimate of d = 0.97 from Wright and colleagues for a difference in IAG levels between 
ASD children and controls (29), we would need 18 children in each group to see a difference 
of this size at a power of 80% and significance level of 5% (two-tailed). Of the 155 controls 
(comprising 121 in main stream schools, 56 of whom were age, sex and school matched for 
the autism spectrum children, and 34 in special school), 145 (113 mainstream and 32 special 
school) had a complete bowel data set (94%). Full diet and bowel data were available for 43 
children on the autism spectrum (80%) and 22 control children in special school (65%). 
(Table 2 shows the gender and age distribution of the participants and Table 3 gives the 
number of various bowel symptoms reported for the different groups.) 
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Figure 1: Distribution for the natural logarithm of IAG:creatinine ratio for children with ASD 
and controls (CON), with and without GI problems (GI and NGI respectively). In each case 
the box is determined by the first and third quartiles of the data, so that 50% of the data lie 
within the box (the interquartile range), with the thick line showing the median. The dashed 
lines extend to the lowest and highest values that are within 1.5 times of the interquartile 
range and data points outside this range are shown individually as circles. 
 Figure 2: Distribution IAG levels for children with GI problems. A constant 0.001 was added 
to IAG levels (measured in mmol) before taking the natural logarithm. The boxplots show the 
distribution for children with ASD (ASD-GI) and controls, in both mainstream (MAIN-GI) 
and special (SPEC-GI) schools. Although the levels are significantly lower for ASD children 
than for mainstream school controls (t-test p = 0.035), the levels for children in special 
schools (without ASD) are also significantly lower than mainstream school controls (t-test p = 
0.004). 
 
 
 
  
Figure 3: Distribution of diet scores for ASD children with GI problems (ASD_GI, N = 25) 
and ASD children without GI problems (ASD_NGI, N =18). 
 
 
 
 
 
 
 
 Figure 4: Distribution of bowel scores for children with ASD with diet problems (labeled 1) 
and without diet problems (labeled 0). 
 
 
 
 
 
 
 
 
 
 Figure 5: Scores for faddiness plotted against diet scores. Circles denote ASD children and 
squares denote special school controls with solid symbols representing children suffering GI 
problems and open symbols representing those without GI problems in each case. 
 
 
 
 
 
 
 
 
 Figure 6: Network analysis on the bowel symptoms for children with ASD. The size of the 
node is related to the number of occurrences of the various symptoms and the thickness of the 
lines indicate the strength of the association between symptoms. 
 
 
 
 
 
 
 
 
 
 
 
Table	1:	Summary	of	IAG	level	comparisons.	
	 Student’s	t-test	 Wilcoxon	test	
ASD-GI	vs	ASD-NGI	 0.199	 0.131	
MAIN-GI	vs	MAIN-NGI	 0.084	 0.100	
SPEC-GI	vs	SPEC-NGI	 0.367	 0.387	
CON-GI	vs	CON-NGI	 0.927	 0.986	
ASD-GI	vs	MAIN-GI	 0.035*	 0.117	
SPEC-GI	vs	MAIN-GI	 0.004*	 0.002*	
ASD-GI	vs	SPEC-GI	 0.457	 0.246	
ASD-GI	vs	CON-GI	 0.596	 0.742	
ASD-GI,	N	=	29;	ASD-NGI,	N	=	22;	MAIN-GI,	N	=	14;	MAIN-NGI,	N	=	99;	CON-GI,	N	=	26;	CON-NGI,	N	=	119;	
SPEC-GI,	N	=	12;	SPEC-NGI,	N	=	20.	The	children	in	the	special	school	group	suffered	from	other	
developmental	disorders,	but	were	not	diagnosed	with	autism.*	Result	significant	at	the	95%	confidence	
level.	
	  
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
	
Table	2:	Gender	and	age	distribution	of	the	participants	included	in	the	analysis	of	IAG	levels.	
	 ASD	group	 Mainstream	school	
control	group	
Special	school	
control	group	
gender	 	
male	 42	 65	 18	
female	 11	 54	 16	
Not	given	 1	 2	 0	
age	(years)	 	
0	-	4		 4	 4	 0	
5	-	8		 17	 52	 4	
9	-	12		 25	 59	 10	
13	-16		 5	 4	 15	
17-20	 3	 2	 5	
age-IAG	
correlationa	
-0.01	 -0.13	 -0.29	
a	Pearson	correlation	coefficient	between	age	and	ln(IAG	+	0.001)	values.	
	  
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
	
	
	
	
Table	3:	The	number	of	participants	providing	bowel	and	diet	data	with	number	of	various	
symptoms	reported	for	each	group.	
	 ASD	group	 Mainstream	school	
control	group	
Special	school	control	
group	
Bowel	data	 51	 113	 32	
Diet	data	 43	 33	 22	
GI	 29	 14	 12	
NGI	 22	 99	 20	
Gastrointestinal	symptoms	
diarrhea	 14	 6	 3	
constipation	 13	 5	 10	
abdominal	pain	 8	 8	 2	
bloating	 7	 4	 2	
flatulence	 12	 2	 4	
blood	in	stool	 4	 1	 0	
 
 
 
 
 
 
 
 
 
 
